ENGOT-EN9/LEAP-001: A phase III, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer

Marth, C.Vulsteke, C.Rubio, M. J.Makker, V.Braicu, E. I.McNeish, I. A.Radoslaw, M.Ayhan, A.Hasegawa, K.Wu, X.Dutta, L.Xu, C.Keefe, S. M.Lee, J.Pıgnata, S.2020-10-202020-10-2020190923-7534http://hdl.handle.net/11727/4935enginfo:eu-repo/semantics/closedAccessENGOT-EN9/LEAP-001: A phase III, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancerconferenceObject30000491295503112